Fractyl Health, Inc. (NASDAQ:GUTS) Insider Jay David Caplan Sells 22,346 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 22,346 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares of the company’s stock, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Jay David Caplan also recently made the following trade(s):

• On Monday, November 11th, Jay David Caplan sold 64,197 shares of Fractyl Health stock. The stock was sold at an average price of $2.47, for a total value of $158,566.59.

Fractyl Health Price Performance

Shares of GUTS opened at $1.70 on Tuesday. The company has a market cap of $81.77 million and a P/E ratio of -0.14. Fractyl Health, Inc. has a fifty-two week low of $1.68 and a fifty-two week high of $13.99. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average price is $2.06 and its 200 day moving average price is $2.51.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. On average, research analysts forecast that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley cut their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of Fractyl Health during the third quarter worth about $25,000. SG Americas Securities LLC acquired a new position in Fractyl Health during the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health in the 2nd quarter valued at approximately $61,000. JPMorgan Chase & Co. raised its holdings in shares of Fractyl Health by 335.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after purchasing an additional 11,406 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter worth $38,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.